Progenics Pharma (NASDAQ: PGNX) reported Q2 EPS of ($0.08), $0.05 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $8.5 million versus the consensus estimate of $6.33 million.

For earnings history and earnings-related data on Progenics Pharma (PGNX) click here.